Our achievements. Our accomplishments. Our impact.



  • Stem Cell Plasticity

    Adult stem cells offer great potential as tools or targets of new treatments, and the Stem Cell Network launched a multidisciplinary project early in its mandate in order to discover more about the nature of these mysterious cells.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Blood Stem Cell Expansion

    Over more than a decade of targeted funding, the Stem Cell Network harnessed the strength of world-leading Canadian researchers to develop technologies to increase quantities of blood stem cells for expanded therapeutic use and to overcome a significant hurdle in the delivery of cell-based treatments to patients.

    READ STORY

  • Cutting-Edge Skills Development

    The Stem Cell Network worked diligently to identify key areas where enhanced training, provided on a national scale, would have direct benefits on research outcomes and also for Canada’s future scientists and clinicians.

    READ STORY

  • Stem Cell Genomics

    SCN’s Gene Expression Project was made possible through the Network’s collaborative approach to research, and the Project’s use of a single centre to undertake a standardized analysis of hundreds of stem cell lines allowed for the creation of pertinent data and meta-data to be accessed by thousands of researchers around the world.

    READ STORY

  • Clinical Trials

    When the Stem Cell Network was first funded, its leadership considered that catalyzing a single clinical trial during its 14-year mandate would have been a success. Instead, the Network’s research investments have led to 12 clinical trials on various diseases, with even more in the development pipeline.

    READ STORY